Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR-3355 Injection in Community-Acquired Pneumonia
jRCT2080220476Phase 3
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of levofloxacin in community-acquired pneumonia (CAP) (2 arms), sponsored by Daiichi Sankyo Co., Ltd.
02
Drugs
levofloxacin
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on jRCT2080220476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220476.